Influence of COVID-19 on the Pharmacovigilance Workforce of the Future.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

3 citing papers in PubMed.

1. Current career situations of Chinese pharmacovigilance professionals working for pharmaceutical companies: an exploratory survey.BMC health services research · 2023
   Article
2. Impact of risk communication on patient's safety during the pandemic.Therapeutic advances in drug safety · 2023
   Review
3. Big data, medicines safety and pharmacovigilance.Journal of pharmaceutical policy and practice · 2021
   Article

Corrections and comments

• Comment on
  Effects of the COVID-19 Pandemic on Spontaneous Reporting: Global and National Time-series Analyses.2021

Authors and funding

1 author.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as